source
- Tiziana's intranasal MS drug shows lower dose cuts neuroinflammation, higher dose falls short in Phase 2a trialTiziana Life Sciences reported results from its mid‑stage Inform‑MS trial, a Phase 2a study that enrolled 48 patients with non‑active secondary progressive multiple sclerosis. Participants received…
- Early Alert: B. Braun Medical Inc. Removes Streamline Bloodline Set for Dialog+The dialyzer connector may not be attached appropriately, resulting in leaking and potential blood loss.